Skip to content

Oral selenium supplementation in acute LRTI in paediatric age group

Role of oral supplementation of selenium as an adjunct therapy in the treatment of acute lower respiratory tract infection for paediatric age group:A quasi experimental non randomized controlled trial - Nil

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/05/111339
Enrollment
164
Registered
2026-05-29
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J069- Acute upper respiratory infection,unspecified Health Condition 2: J069- Acute upper respiratory infection,unspecified

Interventions

Intervention1: Selenium supplemention in acute lower respiratory tract infection: Oral selenium will be supplemented to one group along with ongoing standard treatment and the other group will receive

Sponsors

Dr Sofia kanagaraj
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age group 2 to 5 years included Mechanics ventilated children are also included Clinical diagnosis of acute lower respiratory tract infection are included

Exclusion criteria

Exclusion criteria: 1. Chronic respiratory conditions: o Pre-existing chronic lung diseases (asthma, cystic fibrosis, bronchopulmonary dysplasia). 2. Immunocompromised status: o Known primary or secondary immunodeficiency (HIV, chemotherapy). 3. Congenital anomalies: o Congenital heart disease or major structural lung anomalies. 4. Supplementation: o History of selenium or multivitamin supplementation containing selenium in the last 4 weeks. 5. Allergy or intolerance: o Known allergy to selenium or any component of the supplement. 6. Other concurrent infections: o Suspected or confirmed tuberculosis, or other co-infections needing different management

Design outcomes

Primary

MeasureTime frame
1.The number of days from initiation of treatment until resolution of key symptoms (fever, cough, dyspnea) will be compared in both selenium receiving group and in standard care rec eiving group 2. To explore whether selenium Supplementation contributes to faster clinical recovery such as oxygen saturation, respiratory rate, and temperature between two groupsTimepoint: The results will be assessed after 3 days and then on regular review after one month and three month of treatment completion

Secondary

MeasureTime frame
Duration of Hospital Stay To evaluate the impact of oral selenium Supplementation on hospital stay duration in children with ALRTI Need for Antibiotic Escalation or Change in Treatment To compare the need for antibiotics between children receiving selenium & standard care treatment Duration of Oxygen Requirement To assess the effect of oral selenium Supplementation in terms of oxygen requirements & clinical improvement Timepoint: The results will be assessed after three days of treatment completion And then on regular review after one & three months

Countries

India

Contacts

Public ContactDr Jayakumar

Government omandurar medical college

omcpaeds@gmail.com9176156210

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026